Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6322982A · kind A · utility
0Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 1999 |
| Grant date | Nov 27, 2001 |
| Priority date | — |
| Expiry date | Aug 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The expression of ubiquitin carboxy-terminal hydrolase is aberrent in cells that are resistant to treatment with chemical agents. Accordingly, the invention features methods for diagnosing and treating drug resistant cells (e.g., tumor cells) by examining and modulating the expression or activity of UCH
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.